Data Sheet

Product Name: CXCR2-IN-1
Cat. No.: HY-101022
CAS No.: 1873376-49-8
Molecular Formula: C_{19}H_{20}ClF_{3}N_{3}O_{4}S
Molecular Weight: 476.35
Target: CXCR
Pathway: GPCR/G Protein; Immunology/Inflammation
Solubility: DMSO: ≥5.4 mg/mL (Need ultrasonic and warming)

BIOLOGICAL ACTIVITY:
CXCR2-IN-1 is a central nervous system penetrant CXCR2 antagonists with a pIC_{50} of 9.3.
IC50 & Target: pIC50: 9.3 (CXCR2)[1]

In Vitro: CXCR2 plays an important role in the activation and recruitment of neutrophils to sites of inflammation. CXCR2-IN-1 shows favorable central nervous system penetration property (Br/Bl>0.45)[1].

In Vivo: CXCR2-IN-1 shows efficacy in a cuprizone-induced demyelination model through oral administration, providing evidence to support CXCR2 to be a potential therapeutic target to treat demyelinating diseases such as multiple sclerosis[1].

PROTOCOL (Extracted from published papers and Only for reference)
Animal Administration: [1] Mouse: Mice are fed with cuprizone for 5 weeks to cause demyelinating lesions in the CNS and then orally administrated with CXCR2-IN-1 for 9 consecutive days at doses of 30 and 100 mg/kg twice daily[1].

References:

Caution: Product has not been fully validated for medical applications. For research use only.